Intravenous Immunoglobulin and Multiple Sclerosis

Overview

Journal Clin Rev Allergy Immunol

Specialty Allergy & Immunology

Date 2006 Jan 5

PMID 16391400

Citations 1

Authors

Anat Achiron

Shmuel Miron

Affiliations

Soon will be listed here.

Abstract

Intravenous immunoglobulin (IVIg) has been used as an immunomodulatory therapy for the treatment of multiple sclerosis (MS). In the current review, we summarize the up-to-date data related to IVIg clinical trials in MS, and the suggested mechanisms of action by which IVIg modulates the relevant immunological pathways impaired in MS.

Citing Articles

Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.

Olyaeemanesh A, Rahmani M, Goudarzi R, Rahimdel A Med J Islam Repub Iran. 2016; 30:336.

PMID: 27390706 PMC: 4898867.

References

Abe Y, Horiuchi A, Miyake M, Kimura S . Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev. 1994; 139:5-19. DOI: 10.1111/j.1600-065x.1994.tb00854.x. View

Toyoda M, Zhang X, Petrosian A, Galera O, Wang S, Jordan S . Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol. 1994; 14(3):178-89. DOI: 10.1007/BF01533367. View

Bieber A, Asakura K, Warrington A, Kaveri S, Rodriguez M . Antibody-mediated remyelination: relevance to multiple sclerosis. Mult Scler. 2001; 6 Suppl 2:S1-5; discussion S33. View

Lapointe B, Herx L, Gill V, Metz L, Kubes P . IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain. 2004; 127(Pt 12):2649-56. DOI: 10.1093/brain/awh297. View

Sewell W, Jolles S . Immunomodulatory action of intravenous immunoglobulin. Immunology. 2002; 107(4):387-93. PMC: 1782817. DOI: 10.1046/j.1365-2567.2002.01545.x. View

Andersson U, Bjork L, Andersson J . Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev. 1994; 139:21-42. DOI: 10.1111/j.1600-065x.1994.tb00855.x. View

Hurez V, Kaveri S, Mouhoub A, Dietrich G, Mani J, Klatzmann D . Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol. 1994; 1(5):269-77. View

Hommes O, Sorensen P, Fazekas F, Maas Enriquez M, Koelmel H, Fernandez O . Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004; 364(9440):1149-56. DOI: 10.1016/S0140-6736(04)17101-8. View

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H . Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47(6):707-17. DOI: 10.1002/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q. View

10.

Olsson T, Baig S, Hojeberg B, Link H . Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol. 1990; 27(2):132-6. DOI: 10.1002/ana.410270207. View

11.

Sellebjerg F, Jaliashvili I, Christiansen M, Garred P . Intrathecal activation of the complement system and disability in multiple sclerosis. J Neurol Sci. 1998; 157(2):168-74. DOI: 10.1016/s0022-510x(98)00086-0. View

12.

Sooryanarayana , Prasad N, Bonnin E, Pashov A, Ben Jilani K, Ameisen J . Phosphorylation of Bcl-2 and mitochondrial changes are associated with apoptosis of lymphoblastoid cells induced by normal immunoglobulin G. Biochem Biophys Res Commun. 1999; 264(3):896-901. DOI: 10.1006/bbrc.1999.1592. View

13.

Frenette P, Wagner D . Adhesion molecules--Part II: Blood vessels and blood cells. N Engl J Med. 1996; 335(1):43-5. DOI: 10.1056/NEJM199607043350108. View

14.

Kalanie H, Gharagozli K, Hemmatie A, Ghorbanie M, Kalanie A . Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran. Eur Neurol. 2004; 52(4):202-6. DOI: 10.1159/000082036. View

15.

Confavreux C, Hutchinson M, Hours M, Moreau T . Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998; 339(5):285-91. DOI: 10.1056/NEJM199807303390501. View

16.

Gill V, Doig C, Knight D, Love E, Kubes P . Targeting adhesion molecules as a potential mechanism of action for intravenous immunoglobulin. Circulation. 2005; 112(13):2031-9. DOI: 10.1161/CIRCULATIONAHA.105.546150. View

17.

Nyland H, Nilsen R . Localization of Fc gamma receptors in the human central nervous system. Acta Pathol Microbiol Immunol Scand C. 1982; 90(4):217-21. DOI: 10.1111/j.1699-0463.1982.tb01441.x. View

18.

Wurster U, Haas J . Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry. 1994; 57 Suppl:21-5. PMC: 1016718. DOI: 10.1136/jnnp.57.suppl.21. View

19.

Asakura K, Miller D, Murray K, Bansal R, Pfeiffer S, Rodriguez M . Monoclonal autoantibody SCH94.03, which promotes central nervous system remyelination, recognizes an antigen on the surface of oligodendrocytes. J Neurosci Res. 1996; 43(3):273-281. DOI: 10.1002/(SICI)1097-4547(19960201)43:3<273::AID-JNR2>3.0.CO;2-G. View

20.

Haas J . High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler. 2001; 6 Suppl 2:S18-20; discussion S33. View